News & Media

The production of our molecules of interest is decisively launched

March 19, 2024

It is with enthusiasm that Patrick Charest, B. Sc., P.Eng., CEO in collaboration with Aplantex’s scientific and production team announces the achievement of an important milestone in its strategic plan with the production of the first molecules of interest produced at its Boucherville facility. This is the culmination of several years of efforts to develop an innovative solution for local, low-energy, and carbon-neutral production of high-value plant-based molecules. We have concluded this stage faster than anticipated and the results of external analyses on the purity of our molecules far exceed our expectations. Our discussions with potential customers are all the more convincing.

We have concluded this stage faster than anticipated and the results of external analyses on the purity of our molecules far exceed our expectations

The creation of our photosynthetic plant replicators in collaboration with Quebec universities, the rigorous development of our continuous production process, and the meticulous installation of state-of-the-art equipment by our scientific and production team under the direction of the technical director, Dr. André LeBlanc, Ph. D., leads today to the production of rich biomass and the extraction of several high purity flavonoids of interest including Luteolin, Apigenin, Vitexin, and Orientin.

At this point of execution of our strategic plan, we focus on the production of molecules recognized for their antioxidant, anti-inflammatory, antimicrobial, and anti-aging properties relevant to the needs of the cosmetic, agri-food, and pharmaceutical industries. The ongoing expansion of our facilities will allow us to respond effectively to the interests of leading players in each of these industries.


Other articles of interestView all

April 4, 2024

Julia Roberts and Mother Nature’s powerful message

To know more
March 26, 2024

The CIF acceleration program propels Aplantex

To know more
February 14, 2024

$3.3m in second-round financing

To know more